

## Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Michael J. Joyner, R. Scott Wright, DeLisa Fairweather, Jonathon W. Senefeld, Katelyn A. Bruno, Stephen A. Klassen, Rickey E. Carter, Allan M. Klompas, Chad C. Wiggins, John R.A. Shepherd, Robert F. Rea, Emily R. Whelan, Andrew J. Clayburn, Matthew R. Spiegel, Patrick W. Johnson, Elizabeth R. Lesser, Sarah E. Baker, Kathryn F. Larson, Juan G. Ripoll, Kylie J. Andersen, David O. Hodge, Katie L. Kunze, Matthew R. Buras, Matthew N.P. Vogt, Vitaly Herashevich, Joshua J. Dennis, Riley J. Regimbal, Philippe R. Bauer, Janis E. Blair, Camille M. Van Buskirk, Jeffrey L. Winters, James R. Stubbs, Nigel S. Paneth, Nicole C. Verdun, Peter Marks, Arturo Casadevall

*J Clin Invest.* 2020;130(9):4791-4797. <https://doi.org/10.1172/JCI140200>.

### Clinical Research and Public Health

Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19.

Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA expanded access program for COVID-19 convalescent plasma.

The incidence of all serious adverse events (SAEs), including mortality rate (0.3%), in the first 4 hours after transfusion was <1%. Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality ( $n = 4$ ), transfusion-associated circulatory overload ( $n = 7$ ), transfusion-related acute lung injury ( $n = 11$ ), and severe allergic transfusion reactions ( $n = 3$ ). However, only 2 of 36 SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The 7-day mortality rate was 14.9%.

Given the deadly nature of COVID-19 and the large population of critically ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.

ClinicalTrials.gov NCT04338360.

Mayo Clinic, Biomedical Advanced [...]

**Find the latest version:**

<https://jci.me/140200/pdf>



# Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Michael J. Joyner,<sup>1</sup> R. Scott Wright,<sup>2,3</sup> DeLisa Fairweather,<sup>4</sup> Jonathon W. Senefeld,<sup>1</sup> Katelyn A. Bruno,<sup>4</sup> Stephen A. Klassen,<sup>1</sup> Rickey E. Carter,<sup>5</sup> Allan M. Klompaas,<sup>1</sup> Chad C. Wiggins,<sup>1</sup> John R.A. Shepherd,<sup>1</sup> Robert F. Rea,<sup>2</sup> Emily R. Whelan,<sup>4</sup> Andrew J. Clayburn,<sup>1</sup> Matthew R. Spiegel,<sup>5</sup> Patrick W. Johnson,<sup>5</sup> Elizabeth R. Lesser,<sup>5</sup> Sarah E. Baker,<sup>1</sup> Kathryn F. Larson,<sup>2</sup> Juan G. Ripoll,<sup>1</sup> Kylie J. Andersen,<sup>1</sup> David O. Hodge,<sup>5</sup> Katie L. Kunze,<sup>6</sup> Matthew R. Buras,<sup>6</sup> Matthew N.P. Vogt,<sup>1</sup> Vitaly Herasevich,<sup>1</sup> Joshua J. Dennis,<sup>1</sup> Riley J. Regimbal,<sup>1</sup> Philippe R. Bauer,<sup>7</sup> Janis E. Blair,<sup>8</sup> Camille M. Van Buskirk,<sup>9</sup> Jeffrey L. Winters,<sup>9</sup> James R. Stubbs,<sup>9</sup> Nigel S. Paneth,<sup>10,11</sup> Nicole C. Verdun,<sup>12</sup> Peter Marks,<sup>12</sup> and Arturo Casadevall<sup>13</sup>

<sup>1</sup>Department of Anesthesiology and Perioperative Medicine, <sup>2</sup>Department of Cardiovascular Medicine, and <sup>3</sup>Human Research Protection Program, Mayo Clinic, Rochester, Minnesota, USA. <sup>4</sup>Department of Cardiovascular Medicine and <sup>5</sup>Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, USA. <sup>6</sup>Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, USA. <sup>7</sup>Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA. <sup>8</sup>Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA. <sup>9</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. <sup>10</sup>Department of Epidemiology and Biostatistics and <sup>11</sup>Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA. <sup>12</sup>Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA. <sup>13</sup>Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

**BACKGROUND.** Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19.

**METHODS.** Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA expanded access program for COVID-19 convalescent plasma.

**RESULTS.** The incidence of all serious adverse events (SAEs), including mortality rate (0.3%), in the first 4 hours after transfusion was <1%. Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality ( $n = 4$ ), transfusion-associated circulatory overload ( $n = 7$ ), transfusion-related acute lung injury ( $n = 11$ ), and severe allergic transfusion reactions ( $n = 3$ ). However, only 2 of 36 SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The 7-day mortality rate was 14.9%.

**CONCLUSION.** Given the deadly nature of COVID-19 and the large population of critically ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.

**TRIAL REGISTRATION.** ClinicalTrials.gov NCT04338360.

**FUNDING.** Mayo Clinic, Biomedical Advanced Research and Development Authority (75A50120C00096), National Center for Advancing Translational Sciences (UL1TR002377), National Heart, Lung, and Blood Institute (SR35HL139854 and R01 HL059842), National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK07352), Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019), National Institute of Allergy and Infectious Disease (R21 AI145356, R21 AI152318, and AI152078), Schwab Charitable Fund, United Health Group, National Basketball Association, Millennium Pharmaceuticals, and Octapharma USA Inc.

## Introduction

The number of confirmed cases of coronavirus disease 2019 (COVID-19) and the number of deaths attributed to COVID-19

in the US exceed that of any other country in the world (1). The overall case fatality rate for diagnosed COVID-19 appears to be about 4% (2), and reports from Wuhan suggest case-fatality rates of 14% among hospitalized patients (3) and 57% among patients admitted to the intensive care unit (ICU) on ventilators or requiring a fraction of inspired oxygen >60% (4). The reported fatality rate in the US ranged from 21% in New York City hospitals (5) to 50%, as reported in an early case series from the Seattle area (6). In response to the COVID-19 outbreak in the US and reported case-fatality rates, the US FDA in collaboration


**Conflict of interest:** UnitedHealth Group, Millennium Pharmaceuticals, and Octapharma USA Inc. supported this project.

**Copyright:** © 2020, American Society for Clinical Investigation.

**Submitted:** May 13, 2020; **Accepted:** June 3, 2020; **Published:** August 10, 2020.

**Reference information:** *J Clin Invest.* 2020;130(9):4791–4797.

<https://doi.org/10.1172/JCI140200>.



**Figure 1. Participation in the US COVID-19 convalescent plasma expanded access program, including data extracted on May 11, 2020.**

(A) Choropleth map displaying the number of cumulatively enrolled patients in the expanded access program (EAP) within each state of the contiguous US, with lower enrollment values displayed in a lighter hue of blue and higher enrollment values displayed in a darker hue of blue. Registered acute care facilities are represented as yellow circles, with larger circles indicating greater numbers of registered facilities within the metropolitan area of a city. The choropleth map does not display data from noncontiguous US locations, including registered facilities in Puerto Rico, Hawaii, Alaska, Guam, and Northern Mariana Islands.

(B) The chronological line charts represent the cumulative number of enrolled patients (blue line) and the cumulative number of patients that have received a COVID-19 convalescent plasma transfusion (yellow line). The chronological bar charts represent analogous values – the number of enrolled patients (blue bars) and number of patients that have received a COVID-19 convalescent plasma transfusion (yellow bars) by day. The difference between the blue and yellow bars highlights a fulfillment gap in COVID-19 convalescent plasma, which was most acute at the onset of the EAP and has substantially improved.

with the Mayo Clinic and national blood banking community developed a national expanded access program (EAP) to collect and distribute convalescent plasma donated by individuals that have recovered from COVID-19. There is historical precedent for anticipating that human convalescent plasma is a viable option for mitigation and treatment of COVID-19 (7, 8). Human convalescent plasma uses antibodies harvested from recently infected and currently recovered patients with COVID-19 to treat currently infected patients with COVID-19. This approach is referred to as passive antibody therapy. As recently summarized (7), convalescent plasma represents a promising treatment strategy with a strong historical precedence, biological plausibility, and limited barriers for rapid development and deployment of this investigational therapy.

Passive antibody therapy was first described in the 1890s as the only means of treating certain infectious diseases before the devel-

opment of antimicrobial therapy in the 1940s (9). Convalescent plasma was used during the 1918 flu epidemic and reduced mortality among plasma recipients (10). More recently, 2 other epidemics caused by coronaviruses have been associated with high mortality, severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in 2003 and Middle East respiratory syndrome (MERS) in 2012. The SARS-CoV-1 epidemic was contained, but MERS became endemic in the Middle East and triggered a secondary major outbreak in South Korea. In both viral outbreaks, the high mortality and absence of effective therapies led to the use of convalescent plasma. In the largest study of the SARS-CoV-1 outbreak, among 80 patients in Hong Kong (11), patients treated within the first 14 days of infection had an earlier discharge from the hospital. These results are consistent with the notion that convalescent plasma may be an effective treatment of coronavirus infections and that earlier administration is more likely to be successful.

**Table 1. Patient characteristics**

Age, median (range) <sup>A</sup>	62.3 (18.5, 97.8)
<b>Sex<sup>A</sup></b>	
Women, n (%)	1824 (36.5%)
Men, n (%)	3153 (63.1%)
Intersex or transgender, n (%)	17 (0.3%)
Undisclosed, n (%)	6 (0.1%)
<b>Race<sup>A</sup></b>	
Asian, n (%)	317 (6.3%)
American Indian or Alaska Native, n (%)	40 (0.8%)
Black or African American, n (%)	915 (18.3%)
White, n (%)	2438 (48.8%)
Native Hawaiian or Other Pacific Islander, n (%)	17 (0.3%)
Multiracial, n (%)	23 (0.5%)
Other or unknown, n (%)	1250 (24.8%)
<b>Ethnicity<sup>A</sup></b>	
Hispanic or Latino, n (%)	1733 (34.7%)
Not Hispanic or Latino, n (%)	3267 (65.3%)
<b>Clinical status<sup>A</sup></b>	
Current severe or life-threatening COVID-19, n (%)	4051 (81.0%)
High risk of severe or life-threatening COVID-19, n (%)	949 (19.0%)
Intensive care unit admission, n (%)	3316 (66.3%)
<b>Clinical symptoms<sup>B</sup></b>	
Respiratory failure, n (%)	2912 (71.9%)
Dyspnea, n (%)	2550 (62.9%)
Blood oxygen saturation $\leq$ 93%, n (%)	2519 (62.2%)
Lung infiltrates $>$ 50% within 24–48 hours, n (%)	1721 (42.5%)
Respiratory frequency $\geq$ 30/min, n (%)	1546 (38.2%)
$P_aO_2/F_iO_2$ ratio <sup>C</sup> $<$ 300, n (%)	1365 (33.7%)
Multiple organ dysfunction or failure, n (%)	745 (18.4%)
Septic shock, n (%)	600 (14.8%)

<sup>A</sup>n = 5000. <sup>B</sup>These data include only patients with current severe or life-threatening COVID-19 (n = 4051). <sup>C</sup>The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen ratio.

Although promising, convalescent plasma has not yet been demonstrated to be safe as a treatment for COVID-19. Thus, we analyzed key safety metrics following transfusion of convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19. We hypothesized that the rate of serious adverse events (SAEs) related to the transfusion of convalescent plasma per se would be low and that the 7-day mortality rate would not be demonstrably elevated compared with other experiences with this deadly disease.

## Results

**EAP participation.** From April 3, 2020, to May 11, 2020, a total of 14,288 patients with severe or life-threatening COVID-19 or who were judged by a health care provider to be at high risk of progression to severe or life-threatening COVID-19 were enrolled in the EAP. In that time, a total of 8932 enrolled patients received a COVID-19 convalescent plasma transfusion (Figure 1). Data from the first 5000 transfused patients were included in this report.

**Demographics.** Key demographic characteristics of the patients are presented in Table 1. The data set included 3153 men, 1824 women, and 23 persons in other gender/sex categories, with diverse

racial representation, including people from Asian (6%), American Indian or Alaskan Native (<1%), Black (18%), White (49%), Native Hawaiian or Pacific Islander (<1%), and multiracial (<1%) backgrounds. The median age was 62 years (range, 18–97 years).

**Clinical status and symptoms.** At the time of enrollment, 4051 (81%) patients had severe or life-threatening COVID-19, and 949 (19%) were judged to have a high risk of progressing to severe or life-threatening COVID-19. Before COVID-19 convalescent plasma transfusion, a total of 3316 patients (66%) was admitted to the ICU. Of the 4051 patients diagnosed with severe or life-threatening COVID-19, 72% had respiratory failure, 63% reported dyspnea, 62% had a blood oxygen saturation  $\leq$ 93%, 43% had lung infiltrates  $>$ 50% within 24–28 hours of enrollment, 38% had a respiratory frequency  $\geq$ 30 breaths/min, 34% had partial pressure of arterial oxygen to fraction of inspired oxygen ratio  $<$ 300, 18% had multiple organ dysfunction or failure, and 15% had septic shock.

**SAEs.** Within 4 hours of completion of the COVID-19 convalescent plasma transfusion (inclusive of the plasma transfusion), 36 SAEs were reported (<1% of all transfusions). The attribution scale used by the treating physicians for evaluating the SAEs included unrelated, possibility related, probably related, or definitely related. Of the SAEs, 15 deaths were reported (0.3% of all transfusions) and 4 of those deaths were judged as related (possibly, n = 3; probably, n = 1; definitely, n = 0) to the transfusion of COVID-19 convalescent plasma. There were 21 nondeath SAEs reported, with 7 reports of transfusion-associated circulatory overload (TACO), 11 reports of transfusion-related acute lung injury (TRALI), and 3 reports of severe allergic transfusion reaction. All incidences of TACO and TRALI were judged as related (possibly, n = 9; probably, n = 7; definitely, n = 2) to the transfusion of COVID-19 convalescent plasma. The SAEs and their attributions are summarized in Table 2.

Over the first 7 days after the convalescent plasma transfusion, a total of 602 mortalities were observed. The overall 7-day mortality rate was estimated to be 14.9% (95% CI, 13.8%, 16.0%) using the product limit estimator, an estimate that was numerically higher than the crude estimate of 12.0% at day 7. Of the 3316 patients admitted to the ICU, 456 mortalities were observed (16.7%, 95% CI, 15.3%, 18.1%). Of the 1682 hospitalized patients not admitted to the ICU, 146 mortalities were observed (11.2%, 95% CI, 9.5%, 12.9%).

## Discussion

**Safety summary.** In this initial report of 5000 hospitalized patients in the US with severe or life-threatening COVID-19, or who were judged by a health care provider to be at high risk of progressing to severe or life-threatening COVID-19, the overall frequency of SAEs within 4 hours following the transfusion of COVID-19 convalescent plasma was less than 1% (n = 36) and the 7-day mortality rate was 14.9%. Although 70% of these SAEs were deemed to be related to plasma transfusion by treating physicians, most of the SAEs (56%) were judged as possibly related, suggesting uncertainty about the role of the transfusion per se in the adverse reaction. Additionally, the rate of SAEs definitely related to transfusion was objectively low (n = 2, <0.1% of all transfusions).

Although this study was not designed to evaluate efficacy of convalescent plasma, we note with optimism the relatively low mortality in treated patients. The case fatality rate of COVID-19

**Table 2. Serious adverse event characteristics (n = 5,000)**

Four-hour reports	Reported (n = 36)	Related <sup>A</sup> (n = 25)	Estimate (95% CI)
Mortality	15	4	0.08% (0.03%, 0.21%)
Transfusion-associated circulatory overload	7	7	0.14% (0.07%, 0.29%)
Transfusion-related acute lung injury	11	11	0.22% (0.12%, 0.39%)
Severe allergic transfusion reaction	3	3	0.06% (0.02%, 0.18%)
<b>Seven-day reports</b>			
Mortality	602		14.9% (13.8%, 16.0%) <sup>B</sup>

<sup>A</sup>This category of serious adverse events (SAE) reports the aggregate total of possibly, probably and definitely related SAEs, as attributed based on the site investigator's determination. The estimate is based on the number of related SAEs relative to the denominator of 5,000. <sup>B</sup>The estimated 7-day mortality rate is based on a Kaplan-Meier estimate using all reported deaths. See Methods for further estimation details including handling of censoring due to ongoing data collection.

has been reported to be approximately 4% among all persons diagnosed with COVID-19 (2). However, the case fatality rate among hospitalized patients is much higher and more variable at approximately 10%–20% (3, 5), particularly among patients admitted to the ICU (4). Thus, the 7-day mortality rate of 14.9% reported here is not alarming, particularly because some of these plasma transfusions may be characterized as attempts at rescue or salvage therapy in patients admitted to the ICU with multiorgan failure, sepsis, and significant comorbidities.

Despite these early and encouraging safety signals, there are several risks of COVID-19 convalescent plasma transfusion in critically ill patients that warrant attention in this initial assessment of safety (12, 13).

**TRALI and TACO.** The highest risk of mortality following plasma transfusion is likely due to sequelae pulmonary complications (14), and this risk is probably exacerbated by the underlying respiratory distress associated with COVID-19. TRALI and TACO are the 2 leading causes of transfusion-related mortality, and they are often difficult to distinguish. These conditions have been emphasized in the plasma transfusion literature, but making an unequivocal determination of plasma-related toxicity in critically ill individuals is difficult in the face of ongoing conditions that resemble transfusion SAEs. Consequently, it is likely that some of the reported SAEs represent natural progression of the ongoing pathological processes.

The most common adverse event associated with plasma transfusion in critically ill patients is TACO, which results in pulmonary edema and left atrial hypertension subsequent to circulatory overload. The reported incidence of TACO includes a large range, from 1 in 14,000 in surveillance surveys to 12% in prospective studies in higher risk populations, showing the dependence of incidence on the clinical status of the transfusion recipient

(15–17). TRALI often presents as bilateral pulmonary edema, with little evidence of circulatory overload, and TRALI is further categorized into 2 types based on the absence of acute respiratory distress syndrome (ARDS) risk factors (type I) or presence of ARDS risk factors (type II) (18). The reported incidence of TRALI similarly covers a large range, from approximately 0.01% in surveillance surveys to 8% in prospective studies of the critically ill (19, 20). The underlying lung injury associated with COVID-19 further complicates the differential diagnosis of TACO and TRALI and may exacerbate the risk of transfusion-related reactions in these critically ill patients. Although the incidence of transfusion-related reactions (TACO and TRALI) among critically ill patients may be anticipated to be nearly 10%, the current data demonstrate an overall rate of reported transfusion-related SAEs of less than 1%. Thus, the low rates of TRALI and TACO along with the possibly related attribution of most cases are reassuring.

**Antibody-dependent enhancement.** A theoretical concern of the use of COVID-19 convalescent plasma in patients with COVID-19 is a deteriorated clinical condition after plasma transfusion secondary to antibody-dependent enhancement (ADE) of infection or antibody-mediated proinflammatory effects (21). This theoretical concern is supported by reports of ADE in macaques given specific antibody administration before SARS-CoV-1 experimental infection (22) and ADE effects with other coronaviruses (23, 24). There is also the concern that antibody administration to individuals with significant viral loads may lead to the formation of antigen-antibody immune complexes, which may contribute to proinflammatory immune responses (25, 26). Although the specific signs and symptoms of ADE in humans with coronavirus infection are unknown, such an effect would presumably be associated with clinical deterioration and/or worse outcomes following convalescent plasma administration. The absence of a toxicity signature with the use of convalescent plasma in individuals with COVID-19 implies that this phenomenon may be clinically inconsequential. COVID-19 is known to elicit high neutralizing antibody titers in individuals who have recently recovered from infection, and 3 case series of convalescent plasma administration also describe no deleterious ADE effects after infusion (27–29). The absence of untoward antibody-related effects after convalescent plasma administration could be due to the preferential binding of the neutralizing antibody to the virus rather than to immune cells or tissues that would be needed to enhance the proinflammatory immune responses responsible for ADE (30). Despite the absence of an apparent toxic effect attributable to specific antibody administration thus far, we caution continued vigilance as the use of antibody-based therapies and the number of treated individuals expands, particularly because specific high-risk groups may emerge that were not discernable in this initial cohort.

**Transfusion reactions and coagulation derangements.** Another theoretical risk for convalescent plasma use in COVID-19 is the possibility that it could exacerbate the type of coagulation derangements associated with advanced COVID-19 (31). Absence of clinical outcomes related to severe thrombotic events within the 4-hour SAE reports suggests that administration of 1–2 units of convalescent plasma does not acutely exacerbate potentially underlying disordered coagulation among critically ill patients with COVID-19.

**Limitations.** A key limitation of our observations includes the lack of detailed training of study personnel and monitoring in a highly diverse group of sites ranging from small community hospitals in rural areas to urban public hospitals to full-service academic medical centers. Given the speed at which the EAP was implemented and considering the stress on clinical staff at participating sites during this on-going pandemic, the web-based case reporting forms were designed to optimize convenience. Additionally, although the patient inclusion criteria were specific to hospitalized patients, these criteria were exceptionally broad. While these elements of the EAP may be suboptimal, they are perhaps understandable in a crisis of the magnitude of the COVID-19 pandemic.

The efficacy of convalescent plasma for treatment of COVID-19 has not yet been determined, and this report, focused on safety signals, should not be misconstrued as evidence of effectiveness. To test the efficacy of this therapy, future analyses of EAP data will include exposure control cohorts of patients who did not receive COVID-19 convalescent plasma. However, randomized controlled trials — some of which are currently in progress — will ultimately be necessary to evaluate the potential efficacy of convalescent plasma treatment along the continuum of disease severity (<http://ccpp19.org>). Importantly, evolving data from the EAP will continue to have a high degree of use in understanding the real-world safety of COVID-19 convalescent plasma.

**Conclusion.** In summary, the experience of the first 5000 patients with COVID-19 transfused with convalescent plasma provides no signal of toxicity beyond what is expected from plasma use in severely ill patients. Additionally, given the deadly nature of COVID-19 and the large population of critically ill patients with multiple comorbidities included in these analyses, the mortality rate does not appear excessive. We also note that the data were reviewed by an independent Data and Safety Monitoring Board and have been deposited with the FDA and at no time was there consideration of stopping this therapy. Given the accelerating deployment of this therapy, these emerging data provide early safety indicators of convalescent plasma for COVID-19 treatment and suggest that research should shift focus toward determining the efficacy of convalescent plasma.

## Methods

**Design and oversight.** The program is an FDA-initiated, national, multi-center, open-label EAP in hospitalized adults with severe or life-threatening COVID-19 or who were judged by a health care provider to be at high risk of progression to severe or life-threatening COVID-19. Initial discussions between the FDA and the Mayo Clinic related to the EAP began on March 30th, 2020. All hospitals or acute care facilities in the US (including territories) were eligible to participate. Any willing, licensed US physician could participate as a treating physician–Principal investigator, provided they agreed to adhere to the treatment protocol, the terms of the FDA 1572 form, and all appropriate federal and state regulations. Registration occurred through the EAP central website (<https://www.uscovidplasma.org/>).

The administrative and compliance infrastructure to implement the EAP was rapidly developed, and the initial web-based registration and compliance and data-entry system went live on April 3rd, 2020. The first patient received convalescent plasma on April 7th, 2020, and

more than 5000 hospitalized patients with COVID-19 were transfused with convalescent plasma under the EAP by May 2nd, 2020. Figure 1 illustrates that over 2000 acute care facilities have been registered and over 10,000 patients have been enrolled in the EAP across all 50 states and multiple US territories.

**Participants.** Eligible patients were aged 18 years or older, hospitalized with a laboratory confirmed diagnosis of infection with SARS-CoV-2, and had, or were judged by a health care provider to be at high risk of progression to, severe or life-threatening COVID-19. Severe or life-threatening COVID-19 is defined by 1 or more of the following criterion: dyspnea, respiratory frequency  $\geq 30$  breaths/min, blood oxygen saturation  $\leq 93\%$ , lung infiltrates  $>50\%$  within 24–28 hours of enrollment, respiratory failure, septic shock, and multiple organ dysfunction or failure.

**Procedures.** ABO-compatible COVID-19 convalescent plasma had no minimum neutralizing-antibody titer level and was obtained from a registered or licensed blood collector. Convalescent plasma was donated by COVID-19 survivors who were symptom free for 14 days or more — with confirmed diagnosis via clinical laboratory or antibody test—according to standard blood center procedures. Convalescent plasma (200–500 mL) was administered intravenously according to institutional transfusion guidelines. Patients were continuously monitored with clinical assessments. Web-based standard data reporting surveys were completed 4 hours and 7 days after transfusion, with additional forms used to report SAEs using the Research Electronic Data Capture (REDCap) system. All SAE reports will be independently adjudicated over the course of the study by the IND sponsor and trained designee using the National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol as a framework (13).

**Outcomes.** The primary outcome was to determine the safety of transfusion of COVID-19 convalescent plasma assessed as the incidence and relatedness of SEAs, including death.

**Statistics.** To facilitate the rapid enrollment of participants, sites, and investigators, an electronic data collection system hosted at Mayo Clinic was built using the REDCap system (REDCap, v.9.1.15 Vanderbilt University, Nashville, Tennessee, USA) (32, 33). Raw data were retrieved from REDCap via the application programming interface and subjected to data consistency checks. Data presented in this initial safety report may undergo additional data quality control measures as the study progresses. The proportion of people that experienced 1 of a series of previously defined SAEs was summarized using a point estimate and 95% score CI. To assess mortality, the time (in days) between transfusion and death was examined using the Kaplan-Meier product limit estimator. Participants were censored at their last known vital status, and all reported deaths through 7 days were used to estimate the survival function. Data were censored at 0.25 days for patients that did not have follow-up beyond the initial report at 4 hours after transfusion at time of the analysis. For patients that expired within 24 hours, a survival time of 0.5 days was assigned. Precise time of day for key events was not recorded in the data collection system; thus, these imprecise time estimates were used. The point estimate and 95% CI were estimated at day 7 based on the estimated survival function. All analyses and graphics were produced with R version 3.6.2.

**Study approval.** Written informed consent was obtained from the participant or a legally authorized representative before enrollment, except in jurisdictions allowing deferral of consent for emergency treatment, in which case, consent was obtained to continue participa-

tion. The program was approved on April 1st, 2020 by the Mayo Clinic IRB, which served as the central IRB for all participating facilities and empaneled an independent Data and Safety Monitoring Board to oversee the safety analysis.

## Author contributions

MJJ, NSP, and AC conceptualized the study in collaboration with the US FDA (NCV, PM). MJJ, KAB, DF, ERW, and AJC developed data reporting tools. REC, AMK, RFR, MNPV, JEB, NCV, and PM reviewed and evaluated SAE reports. SEB, KFL, VH, JGR, KJA, PRB, CMVB, JLW, and JRS conceptualized data reporting metrics. REC, DOH, MRS, ERL, PWJ, MRB, KLK, JJD, and RJR analyzed the data. MJJ, REC, JWS, SAK, RSW, and AMK interpreted the results. MJJ, JWS, SAK, DF, AMK, CCW, JRAS, NSP, and AC wrote the manuscript. RSW oversaw, developed, and coordinated the IRB and compliance-related infrastructure required to rapidly initiate the EAP in parallel with the activities above. All authors reviewed and edited the manuscript.

## Acknowledgments

This study was supported in part by a US Department of Health and Human Services Biomedical Advanced Research and Development Authority contract (75A50120C00096, to MJJ), a National Center for Advancing Translational Sciences grant (UL1TR002377), a National Heart, Lung, and Blood Institute grant (5R35HL139854, to MJJ), the National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK07352, to JWS and

CCW), the Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019, to SAK), the National Institute of Allergy and Infectious Disease (R21 AI145356 and R21 AI152318, to DF; R01 AI1520789, to AC), the National Heart, Lung, and Blood Institute (R01 HL059842, to AC), the Schwab Charitable Fund (Eric E. Schmidt and Wendy Schmidt donors), the United Health Group, the National Basketball Association, Millennium Pharmaceuticals, Octapharma USA Inc., and the Mayo Clinic. We thank the members of the Mayo Clinic IRB, the Mayo Clinic Office of Human Research Protection; the Mayo Clinic Office of Research Regulatory Support and in particular Mark Wentworth; the Executive Dean of Research at Mayo Clinic, Gregory Gores, and the CEO of Mayo Clinic, Gianrico Farrugia, for their support and assistance; and the independent Data and Safety Monitoring Board for their work and oversight of the EAP, Allan S. Jaffe (chair), David O. Warner, William G. Morice II, Paula J. Santrach, Robert L. Frye, Lawrence J Appel, and Taimur Sher. We thank the members of the National COVID-19 Convalescent Plasma Project (<http://ccpp19.org>) for their intellectual contributions and support. We thank the participating medical centers and medical teams and blood centers for their rigorous efforts necessary to make this program possible. We also thank the donors for providing COVID-19 convalescent plasma.

Address correspondence to: Michael J. Joyner, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, USA. Phone: 507.255.4288; E-mail: joyner.michael@mayo.edu.

1. CDC. Coronavirus disease 2019 (COVID-19): cases in US. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>. Updated June 24, 2020. Accessed June 25, 2020.
2. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate [published online March 27, 2020]. *Lancet Infect Dis*. [https://doi.org/10.1016/s1473-3099\(20\)30244-9](https://doi.org/10.1016/s1473-3099(20)30244-9).
3. Wang K, Zhang Z, Yu M, Tao Y, Xie M. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study [published online April 23, 2020]. *Intensive Care Med*. <https://doi.org/10.1007/s00134-020-06047-w>.
4. Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475–481.
5. Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area [published online April 22, 2020]. *JAMA*. <https://doi.org/10.1001/jama.2020.6775>.
6. Bhatraju PK, et al. Covid-19 in critically ill patients in the Seattle region - case series. *N Engl J Med*. 2020;382(21):2012–2022.
7. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. *J Clin Invest*. 2020;130(4):1545–1548.
8. Zhang JS, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. *J Med Virol*. 2005;77(2):147–150.
9. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis*. 1995;21(1):150–161.
10. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*. 2006;145(8):599–609.
11. Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):44–46.
12. Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC. *National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol*. CDC; 2018. <http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf>. Accessed June 25, 2020.
13. Dzik S. COVID-19 convalescent plasma: now is the time for better science. *Transfus Med Rev*. 2020;null:S0887-7963(20)30026-2.
14. Poles D, et al., on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. Narayan S, ed. *The 2018 Annual SHOT Report*. SHOT; 2019. <https://www.notifylibrary.org/sites/default/files/SHOT%20Annual%20Report%202018.pdf>. Accessed June 25, 2020.
15. Bosboom JJ, et al. Transfusion-associated circulatory overload: a clinical perspective. *Transfus Med Rev*. 2019;33(2):69–77.
16. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. *J Bone Joint Surg Am*. 1999;81(1):2–10.
17. Marshall AL, et al. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. *J Thromb Haemost*. 2016;14(2):324–330.
18. Vlaar APJ, et al. A consensus redefinition of transfusion-related acute lung injury. *Transfusion*. 2019;59(7):2465–2476.
19. Gajic O, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. *Am J Respir Crit Care Med*. 2007;176(9):886–891.
20. Vlaar AP, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. *Crit Care Med*. 2010;38(3):771–778.
21. de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. *EBioMedicine*. 2020;55:102768.
22. Liu L, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI Insight*. 2019;4(4):123158.
23. Wan Y, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. *J Virol*. 2020;94(5):e02015-19.
24. Yip MS, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. *Virol J*. 2014;11:82.
25. Lutz HU. How immune complexes from certain IgG Nabs and any F(ab')2 can mediate excessive complement activation. *Adv Exp Med Biol*. 2012;750:186–196.

26. Jancar S, Sánchez Crespo M. Immune complex-mediated tissue injury: a multistep paradigm. *Trends Immunol.* 2005;26(1):48–55.

27. Duan K, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA.* 2020;117(17):9490–9496.

28. Shen C, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma [published online March 27, 2020]. *JAMA.* <https://doi.org/10.1001/jama.2020.4783>.

29. Zhang B, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection [published online March 31, 2020]. *Chest.* <https://doi.org/10.1016/j.chest.2020.03.039>.

30. Kam YW, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc<sub>γ</sub>RII-dependent entry into B cells in vitro. *Vaccine.* 2007;25(4):729–740.

31. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *J Clin Virol.* 2020;127:104362.

32. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377–381.

33. Harris PA, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.